← Leaderboards
Carlos Milla
University Of Minnesota
$5,468,189
Attributed
$7,005,454
Total exposure
11
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $641.6K · FY2006–25$1M$750K$500K$250K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,005,454 · 11
By mechanism
P01$2,914,285 · 1
R33$1,899,172 · 1
R01$1,678,619 · 1
R21$406,726 · 1
M01$106,652 · 7
Top collaborators
- Sam Emaminejad5 shared
- Sriram Sankararaman5 shared
Others in their field
Top investigators on “Cohort”
- David R. Weir · University Of Michigan At Ann Arbor$406,814,098
- George R Seage · Abt Associates, Inc.$297,656,361
- Eric Jeffrey Topol · Cleveland Clinic Lerner Col/Med-Cwru$242,146,554
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$227,738,417
- Lawrence Corey · Fred Hutchinson Cancer Center$227,738,417
- James Dennis Neaton · Northwestern University$203,539,316
Research focus
CohortSamplingResponseCystic Fibrosis PatientsCystic FibrosisExperimental StudyHuman SubjectPhysiologicalClinical ResearchLungLung TransplantationElastasesLiquid SubstanceTranslationsBiological MarkersRandomizedBaseAztreonamAlgorithmsEngineeringEffective TherapyBloodDisease ManagementDesign
Grant awards (21)
An Autonomous, Non-invasive, and Bioanalytics-enabled Wearable Platform for Precision Nutrition and Personalized Medicine$641,612
R33 · FY2025 · DK
An Autonomous, Non-invasive, and Bioanalytics-enabled Wearable Platform for Precision Nutrition and Personalized Medicine$615,948
R33 · FY2024 · DK
An Autonomous, Non-invasive, and Bioanalytics-enabled Wearable Platform for Precision Nutrition and Personalized Medicine$641,612
R33 · FY2023 · DK
Pathogenesis of Pf Bacteriophages in Pseudomonas Cystic Fibrosis lung Infections$419,459
R01 · FY2022 · HL · contact PI
An Autonomous, Non-invasive, and Bioanalytics-enabled Wearable Platform for Precision Nutrition and Personalized Medicine$195,930
R21 · FY2022 · DK
Pathogenesis of Pf Bacteriophages in Pseudomonas Cystic Fibrosis lung Infections$419,459
R01 · FY2021 · HL · contact PI
An Autonomous, Non-invasive, and Bioanalytics-enabled Wearable Platform for Precision Nutrition and Personalized Medicine$210,796
R21 · FY2021 · DK
Pathogenesis of Pf Bacteriophages in Pseudomonas Cystic Fibrosis lung Infections$419,459
R01 · FY2020 · HL · contact PI
Pathogenesis of Pf Bacteriophages in Pseudomonas Cystic Fibrosis lung Infections$420,242
R01 · FY2019 · HL · contact PI
Biomarker Core$527,888
P01 · FY2015 · HL · contact PI
Biomarker Core$587,803
P01 · FY2014 · HL · contact PI
Biomarker Core$580,034
P01 · FY2013 · HL · contact PI
Biomarker Core$609,280
P01 · FY2012 · HL · contact PI
Biomarker Core$609,280
P01 · FY2011 · HL · contact PI
A PHASE 3, DOUBLE-BLIND, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED TRIAL WITH$36,659
M01 · FY2007 · RR · contact PI
INHALED SODIUM PYRUVATE FOR THE TREATMENT OF CYSTIC FIBROSIS A PHASE I, DOUBLE$9,351
M01 · FY2007 · RR · contact PI
A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, 28-DAY STUDY OF DENUFOSOL TETRAS$9,351
M01 · FY2007 · RR · contact PI
A PHASE 3, DOUBLE-BLIND, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED TRIAL WITH$24,749
M01 · FY2006 · RR · contact PI
A MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, 28-DAY STUDY OF D$17,216
M01 · FY2006 · RR · contact PI
ASSESSMENT OF INDUCED SPUTUM AS A TOOL TO EVALUATE ANTI-INFLAMMATORY AGENTS IN C$8,608
M01 · FY2006 · RR · contact PI
MULTI-CENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE II STUDY OF AEROSOLIZED TG$718
M01 · FY2006 · RR · contact PI